Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial
European Respiratory Journal · 2023-06 · 61 (6) · 2202071
DOI: 10.1183/13993003.02071-2022 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 25.05.2023. Verfasst von Julie Mankikian und 33 weiteren Autor:innen. Beteiligte Einrichtung: CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Interstitial Pneumonias. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy.
Methods
In a randomised, double-blind, two-parallel group, placebo-controlled trial ( NCT02990286 ), patients with connective tissue disease-associated ILD or idiopathic interstitial pneumonia (with or without autoimmune features) and a NSIP pattern (defined on NSIP pathological pattern or on integration of clinicobiological data and a NSIP-like high-resolution computed tomography pattern) were randomly assigned in a 1:1 ratio to receive rituximab (1000 mg) or placebo on day 1 and day 15 in addition to MMF (2 g daily) for 6 months. The primary end-point was the change in percent predicted forced vital capacity (FVC) from baseline to 6 months analysed by a linear mixed model for repeated measures analysis. Secondary end-points included progression-free survival (PFS) up to 6 months and safety.
Findings
Between January 2017 and January 2019, 122 randomised patients received at least one dose of rituximab (n=63) or placebo (n=59). The least-squares mean change from baseline to 6 months in FVC (% predicted) was +1.60 ( se 1.13) in the rituximab+MMF group and −2.01 ( se 1.17) in the placebo+MMF group (between-group difference 3.60, 95% CI 0.41–6.80; p=0.0273). PFS was better in the rituximab+MMF group (crude hazard ratio 0.47, 95% CI 0.23–0.96; p=0.03). Serious adverse events occurred in 26 (41%) patients of the rituximab+MMF group and in 23 (39%) of the placebo+MMF group. Nine infections were reported in the rituximab+MMF group (five bacterial infections, three viral infections, one other) and four bacterial infections in the placebo+MMF group.
Interpretation
Combination of rituximab and MMF was superior to MMF alone in patients with ILD and a NSIP pattern. The use of this combination must take into consideration the risk of viral infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France.
- CIC, INSERM 1415, CHRU Tours, Tours, France.
- Methods in Patients-Centered Outcomes and Health Research, INSERM UMR 1246, Nantes, France.
- Service de Pneumologie, Centre de Compétences des Maladies Pulmonaires Rares, APHM, CHU Nord, 13015 Marseille, France.
- Aix Marseille Université, Marseille, France.
- CHRU Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance, Tours, France.
ORCID-Profile: Raphael Borie, Bruno Crestani, Stéphane Jouneau, Charles-Hugo Marquette, Laurent Plantier, Victor Valentin, Yurdagul Uzunhan, Vincent Cottin, Sylvain Marchand-Adam
Zitieren
APA
Mankikian, J., Caille, A., Reynaud-Gaubert, M., Agier, M. S., Bermudez, J., Bonniaud, P., Borie, R., Brillet, P. Y., Cadranel, J., Court-Fortune, I., Crestani, B., Debray, M. P., Gomez, E., Gondouin, A., Hirschi-Santelmo, S., Israel-Biet, D., Jouneau, S., Juvin, K., Leger, J., …, & EVER-ILD investigators and the OrphaLung network (2023). Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. European Respiratory Journal, 61(6), 2202071. https://doi.org/10.1183/13993003.02071-2022
Vancouver
Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. European Respiratory Journal. 2023;61(6):2202071. doi:10.1183/13993003.02071-2022
BibTeX
@article{Mankikian2023,
author = {Mankikian, Julie and Caille, Agnès and Reynaud-Gaubert, Martine and Agier, Marie-Sara and Bermudez, Julien and Bonniaud, Philippe and Borie, Raphael and Brillet, Pierre-Yves and Cadranel, Jacques and Court-Fortune, Isabelle and Crestani, Bruno and Debray, Marie-Pierre and Gomez, Emmanuel and Gondouin, Anne and Hirschi-Santelmo, Sandrine and Israel-Biet, Dominique and Jouneau, Stéphane and Juvin, Karine and Leger, Julie and Kerjouan, Mallorie and Marquette, Charles-Hugo and Naccache, Jean-Marc and Nunes, Hilario and Plantier, Laurent and Prevot, Grégoire and Quetant, Sébastien and Traclet, Julie and Valentin, Victor and Uzunhan, Yurdagul and Wémeau-Stervinou, Lidwine and Bejan-Angoulvant, Theodora and Cottin, Vincent and Marchand-Adam, Sylvain and EVER-ILD investigators and the OrphaLung network, EVER-ILD investigators and the OrphaLung network},
title = {Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial},
journal = {European Respiratory Journal},
year = {2023},
volume = {61},
number = {6},
pages = {2202071},
doi = {10.1183/13993003.02071-2022}
}
EUVIMED